BIOC insider filings
BIOCEPT INC — 30 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2022-11-18. Screen BIOC transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for BIOC between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — BIOCEPT INC
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2022-11-18 | 4 | DAO-HADDOCK QUYEN THI — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2022-09-08 | 4 | Chandler Marsha Alpert — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2022-09-08 | 4 | Rubinstein Linda M — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2022-09-08 | 4 | Gerhardt Bruce — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2022-09-08 | 4 | Wilson Margaret Faye — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2022-09-08 | 4 | ROYSTON IVOR — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2022-04-04 | 4 | Taylor Darrell — See remarks | Grant/award (A): 15,450 (derivative) @ $0 | EDGAR |
| 2022-04-04 | 4 | Marchand Philippe — Chief Operations Officer | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2022-03-16 | 4 | Taylor Darrell — Sr. V.P., General Counsel | Grant/award (A): 134,550 (derivative) @ $0 | EDGAR |
| 2022-03-02 | 4 | Riccitelli Samuel D — Interim President and CEO, Director | Grant/award (A): 250,000 (derivative) @ $0 | EDGAR |
| 2022-03-02 | 4 | Morales Antonino — Interim CFO, Director | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2021-12-10 | 4 | HALE DAVID F — Director | Sale (S): 363 @ $4.06 · Sale (S): 11 @ $4.07 · Sale (S): 71 @ $4.07 | EDGAR |
| 2021-09-02 | 4 | Nall Michael W. — CEO & President, Director | Grant/award (A): 100,000 (derivative) @ $0 · Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2021-09-02 | 4 | TERRY MICHAEL J — Sr VP of Business Development | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2021-09-02 | 4 | DUGAN MICHAEL C — Chief Med Off & Med. Director | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2021-09-02 | 4 | Kennedy Timothy — CFO, COO & Secretary | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2021-07-20 | 4 | Wilson Margaret Faye — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2021-07-20 | 4 | Gerhardt Bruce — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2021-07-20 | 4 | Chandler Marsha Alpert — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2021-07-20 | 4 | Riccitelli Samuel D — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2021-07-20 | 4 | Rubinstein Linda M — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2021-07-20 | 4 | Morales Antonino — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2021-07-20 | 4 | ROYSTON IVOR — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2021-07-20 | 4 | HALE DAVID F — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2020-10-22 | 4 | Riccitelli Samuel D — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2020-10-05 | 4 | TERRY MICHAEL J — Sr VP Comm. Operations | Grant/award (A): 48,300 (derivative) @ $0 | EDGAR |
| 2020-10-05 | 4 | Kennedy Timothy — CFO, Sr V.P. Operations & Sec. | Grant/award (A): 138,000 (derivative) @ $0 | EDGAR |
| 2020-10-05 | 4 | DUGAN MICHAEL C — Chief Med Off & Med. Director | Grant/award (A): 69,000 (derivative) @ $0 | EDGAR |
| 2020-10-05 | 4 | Nall Michael W. — CEO & President, Director | Grant/award (A): 241,500 (derivative) @ $0 | EDGAR |
| 2020-09-01 | 4 | DUGAN MICHAEL C — Chief Med Off & Med. Director | Grant/award (A): 54,900 (derivative) @ $0 | EDGAR |
Recent 8-K events — BIOCEPT INC
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2023-10-20 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2023-10-16 | 8-K | 1.03 — Bankruptcy or Receivership 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2023-08-22 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-06-21 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2023-05-16 | 8-K | 3.03 — Material Modification to Rights of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-05-15 | 8-K | 2.02 — Results of Operations and Financial Condition 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-04-17 | 8-K | 4.02 — Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review | EDGAR |
| 2023-04-17 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-04-10 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 3.03 — Material Modification to Rights of Security Holders 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-03-20 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=BIOC returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs